Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study)

Juan, José de; Hoya, Pablo Saíz de la; Marco, A; Antón, J.; Faraco, I; Yllobre, C; Pozo, Edelmira; Hoyos, Carmen Hoyos

doi:10.1097/meg.0000000000000163

Cited by 11 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 6,107 articles were identified from the three electronic databases covering the broad project areas, of which 21 articles on HCV treatment in prison settings were included after applying the inclusion and exclusion criteria . From the grey literature, 11 conference abstracts and 2 unpublished research reports were included after applying the inclusion and exclusion criteria and check for duplicity with the peer‐reviewed literature .…”

Section: Resultsmentioning

confidence: 99%

“…Table shows the characteristics of the included studies. There were 2 RCTs and 29 observational studies, including 1 cohort study, 1 nested case‐control study, 1 comparative study, 24 descriptive longitudinal studies and 2 descriptive cross‐sectional studies . Moreover, three cost‐effectiveness studies were included .…”

Section: Resultsmentioning

confidence: 99%

“…Moreover, three cost‐effectiveness studies were included . Twenty‐one studies were conducted in the EU/EEA region . Sample sizes ranged from 24 to 1428.…”

Section: Resultsmentioning

confidence: 99%

“…The study quality of the peer‐reviewed literature was mostly graded as low to very low. Twenty‐nine of the 34 studies reported on the effectiveness of different treatment models of care to achieve an SVR or to complete HCV treatment, 3 studies reported on cost‐effectiveness of HCV treatment, and 29 studies reported on acceptability of and/or barriers to HCV treatment …”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA

Vroling¹,

Oordt-Speets²,

Madeddu

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Hepatitis C prevalence in prison populations is much higher than in the community. Effective hepatitis C treatment within this population does not only have a direct individual health benefit, but may lead to substantial community dividend. We reviewed available evidence on hepatitis C treatment in prison settings, with a focus on the European Union/European Economic Area. A systematic review of the literature (PubMed, EMBASE, Cochrane library) was performed and complemented with searches for conference abstracts and grey literature. Thirty-four publications were included reporting on the effectiveness, acceptability and economic aspects of hepatitis C virus treatment models of care to achieve treatment completion and sustained viral response in prison settings. Available evidence shows that hepatitis C treatment in prison settings is feasible and the introduction of direct-acting antivirals will most likely result in increased treatment completion and better clinical outcomes for the prison population, given the caveats of affordability and the need for increased funding for prison health, with the resulting benefits accruing mostly in the community.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…Moreover, three cost‐effectiveness studies were included . Twenty‐one studies were conducted in the EU/EEA region . Sample sizes ranged from 24 to 1428.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA

Vroling¹,

Oordt-Speets²,

Madeddu

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…In inmates the main cause of discontinuation was release from prison, in which case information regarding the completion of the treatment and the achievement of SVR was very often lost. The difficulty of continuing the treatment after release has often been cited 8,19,[26][27][28][29] and is the main obstacle to obtaining SVR when the treatment is initiated in prison. This problem was also cited by McDonald 20 and Bouteille-Gaillet, 21 who reported rates of missing cases due to release of 28% and 27%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Comparison of effectiveness and discontinuation of interferon‐free therapy for hepatitis C in prison inmates and noninmates

Marco¹,

Roget

Cervantes

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Chronic hepatitis C treatment with direct acting antiviral (DAA) therapy during incarceration is an attractive option, due to its short duration and to the possibility of directly observed treatment or supervision. The aim of this study is to compare the effectiveness and rates of discontinuation of DAA treatment in prisoners and nonprisoners. We studied all patients treated in the 10 prisons of Catalonia and at 3 public hospitals in the Barcelona area between 1 January 2015 and 30 April 2016. We analysed sustained viral response (SVR) and rates of discontinuation through intention-to-treat and modified-intention-to-treat analyses, the latter excluding discontinuations due to release from prison. One hundred and eighty-eight inmates and 862 noninmates were included. Prisoners were significantly younger than nonprisoners, with higher proportions of men, drug users, HIV infection, genotypes 1a and 3 and more treatment with psychiatric drugs. Overall, 98.4% of patients completed treatment. The discontinuation rate was low, but higher in inmates (3.7% vs 1.2% noninmates; P = .003) and in community patients >65 years old (2.8% vs 1.2% in under 65 seconds; P = .008). Among the inmates, 7 (42.8%) discontinuations were due to release. SVR was 93.1% in inmates vs 96.5% in noninmates (P = .08) by intention-to-treat and 95.1% vs 96.5% (P = .37) by modified intention-to-treat. Virologic failure rates were similar (3.8% vs 3% in noninmates; P = .60). SVR, virologic failure and discontinuation rates were similar in inmates and noninmates. Currently, prisons are considered a priority for the implementation of DAA. Improved coordination between penitentiary and community health systems would help to ensure therapeutic continuity in released prisoners.

show abstract

HCV Management in the Incarcerated Population: How Do We Deliver on This Important Front?

Crespo

Llerena

Cobo³

et al. 2019

Curr Hepatology Rep

View full text Add to dashboard Cite

Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study)

Cited by 11 publications

References 20 publications

A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA

A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA

Comparison of effectiveness and discontinuation of interferon‐free therapy for hepatitis C in prison inmates and noninmates

HCV Management in the Incarcerated Population: How Do We Deliver on This Important Front?

Contact Info

Product

Resources

About